Navigation Links
Medivation Announces Pricing of Public Offering
Date:5/27/2009

SAN FRANCISCO, May 27 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the pricing of its public offering of 2,750,000 shares of its common stock at a public offering price of $21.00 per share. The company expects to complete the sale of these shares on or about June 2, 2009. The company has granted the underwriters a 30-day option to purchase 412,500 additional shares of common stock to cover over-allotments, if any.

J.P. Morgan Securities Inc. is acting as sole book-running manager of the offering.

The company currently expects to use the net proceeds of this offering for general corporate purposes, including to support further research, development and commercialization of its product candidates, including its lead product candidate, Dimebon, and its product candidate MDV3100.

The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on August 3, 2007, that has been declared effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Copies of the prospectus supplement and related prospectus relating to the offering may be obtained from J.P. Morgan's prospectus department at 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245, Attention Prospectus Department (telephone number 718-242-8002).

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options.

Forward-looking statements

This news release contains "forward-looking statements" of Medivation within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding expectations as to completion of the public offering. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks and uncertainties related to the financial markets. Reference should be made to Medivation's Annual Report on Form 10-K for the year ended December 31, 2008, filed with the Securities and Exchange Commission under the heading "Risk Factors" for a more detailed description of such factors, as well as the Company's subsequent quarterly report on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Medivation undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
2. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
3. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
4. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
5. Medivation Presents New Data on Dimebons Novel Mechanism of Action
6. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
7. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
8. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
9. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
10. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
11. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... ... a redesigned, easier-to-navigate website for all six of their healthcare job boards. ... dentists, pharmacists, physical and occupational therapists, and biotechnicians, DocCafe.com and the MedJobCafe.com ...
(Date:6/22/2017)... Germany (PRWEB) , ... June 22, 2017 , ... ... is taking over the allergy specialists DST Diagnostische Systeme & Technologien GmbH, thereby ... all know someone who suffers from hay fever, urticaria, asthma, atopic eczema or ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... release of Limfinity® version 6.5, a content-packed update to the Limfinity® framework. , ... a larger and more diverse base of customers among labs and other businesses. ...
(Date:6/20/2017)... NEWTOWN SQUARE, Pa. , June 20, 2017 /PRNewswire/ ... technology, is pleased to announce the issuance of a ... treating gout or hyperuricemia by the U.S. Patent and ... Biotech Inc., a winner of the Buzz of Bio ... , is akin to developing non-drug approaches to ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
(Date:3/24/2017)... , March 24, 2017 The Controller General of ... Mr. Abdulla Algeen have received the prestigious international IAIR Award ... Continue Reading ... ... and Deputy Controller Abdulla Algeen (small picture on the right) have received ...
Breaking Biology News(10 mins):